XSHG
600812
Market cap1.40bUSD
Oct 09, Last price
6.03CNY
1D
10.04%
1Q
30.80%
Jan 2017
-3.67%
Name
North China Pharmaceutical Co.
Chart & performance
P/E
56.52
P/S
1.12
EPS
0.11
Div yield, %
0.55%
Shrs. gr., 5y
1.02%
Rev. gr., 5y
-4.27%
Revenues
9.24b
-6.36%
Net income
183m
+44.15%
CFO
1.18b
-4.31%
Dividend
Jun 11, 20260.035 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
North China Pharmaceutical Company Ltd. is a Chinese firm specializing in the chemical pharmaceutical sector. Its extensive product range primarily features anti-infective medications, supplied as active pharmaceutical ingredients (APIs), their intermediates, and final preparations. The company's offerings further encompass biotechnological therapeutics, drugs for cardiovascular conditions, immunomodulators, vitamin-based consumer health products, and specialized pharmaceuticals for agricultural and veterinary applications. Founded in 1953, North China Pharmaceutical Company Ltd. maintains its headquarters in Shijiazhuang, China.
Key people
Wenfu Liu
Vice Chairman of the Board, General Manager · since 2009
Renlong Gao
Deputy General Manager · since 2007
Guitong Liu
Deputy General Manager, Director · since 2009
Jie Tong
Deputy General Manager · since 2012
Mingsheng Zhou
Chief Economist · since 2011
Haijing Yang
Chairman of the Board, Finance Director, Chief Accounting Officer, Secretary of the Board · since 2015
Ling Wei
Director · since 2011
Jinting Wang
Independent Director · since 2012
Headquarters & legal address
市石家庄市和平东路388号
石家庄市, HE 100000
CN
石家庄市, HE 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||